
Alpha-synuclein inhibitors - Pipeline Insight, 2025
Description
DelveInsight’s, “Alpha-Synuclein Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Alpha-Synuclein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Alpha-Synuclein Inhibitors: Overview
α-Synuclein is a highly soluble unfolded protein that accumulates in Lewy bodies and Lewy neurites in Parkinson disease and other synucleinopathies. It is abundant in the brain, while smaller amounts are found in the heart, muscle and other tissues. In the brain, alpha-synuclein is found mainly at the tips of neurons in specialized structures called presynaptic terminals
Function - Although the function of alpha-synuclein is not well understood, studies suggest that it plays a role in restricting the mobility of synaptic vesicles, consequently attenuating synaptic vesicle recycling and neurotransmitter release. An alternate view is that alpha-synuclein binds to VAMP2 (a synaptobrevin) and stabilizes SNARE complexes; though recent studies indicate that alpha-synuclein–VAMP2 binding is critical for alpha-synuclein-mediated attenuation of synaptic vesicle recycling, connecting the two seemingly divergent views. It may also help regulate the release of dopamine, a type of neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements.
Alpha-Synuclein Inhibitors - Synucleinopathies are a group of disorders characterized by the accumulation of α-Synuclein amyloid inclusions in the brain. Preventing α-Synuclein aggregation is challenging because of the disordered nature of the protein and the stochastic nature of fibrillogenesis, but, at the same time, it is a promising approach for therapeutic intervention in these pathologies.
Alpha-Synuclein Inhibitors Emerging Drugs Chapters
This segment of the Alpha-Synuclein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha-Synuclein Inhibitors Emerging Drugs
Further product details are provided in the report……..
Alpha-Synuclein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Alpha-Synuclein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Alpha-Synuclein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-Synuclein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-Synuclein Inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Alpha-Synuclein Inhibitors: Overview
α-Synuclein is a highly soluble unfolded protein that accumulates in Lewy bodies and Lewy neurites in Parkinson disease and other synucleinopathies. It is abundant in the brain, while smaller amounts are found in the heart, muscle and other tissues. In the brain, alpha-synuclein is found mainly at the tips of neurons in specialized structures called presynaptic terminals
Function - Although the function of alpha-synuclein is not well understood, studies suggest that it plays a role in restricting the mobility of synaptic vesicles, consequently attenuating synaptic vesicle recycling and neurotransmitter release. An alternate view is that alpha-synuclein binds to VAMP2 (a synaptobrevin) and stabilizes SNARE complexes; though recent studies indicate that alpha-synuclein–VAMP2 binding is critical for alpha-synuclein-mediated attenuation of synaptic vesicle recycling, connecting the two seemingly divergent views. It may also help regulate the release of dopamine, a type of neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements.
Alpha-Synuclein Inhibitors - Synucleinopathies are a group of disorders characterized by the accumulation of α-Synuclein amyloid inclusions in the brain. Preventing α-Synuclein aggregation is challenging because of the disordered nature of the protein and the stochastic nature of fibrillogenesis, but, at the same time, it is a promising approach for therapeutic intervention in these pathologies.
Alpha-Synuclein Inhibitors Emerging Drugs Chapters
This segment of the Alpha-Synuclein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha-Synuclein Inhibitors Emerging Drugs
- R-phenserine: Annovis Bio
- UCB 0599: UCB Biopharma
Further product details are provided in the report……..
Alpha-Synuclein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Alpha-Synuclein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Alpha-Synuclein Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Alpha-Synuclein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-Synuclein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-Synuclein Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Alpha-Synuclein Inhibitors R&D. The therapies under development are focused on novel approaches for Alpha-Synuclein Inhibitors.
- Alpha-Synuclein Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Alpha-Synuclein Inhibitors drugs?
- How many Alpha-Synuclein Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Alpha-Synuclein Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha-Synuclein Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alpha-Synuclein Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Annovis Bio
- UCB Biopharma
- Alterity Therapeutics
- Denali Therapeutics Inc
- Lundbeck A/S
- AbbVie
- Prevail Therapeutics
- United Neuroscience
- AstraZeneca
- Nitrome Biosciences
- Enterin
- AFFiRiS
- Prothena Corporation
- Roche
- Proclara Biosciences
- Modag
- ProMIS Neurosciences
- R-phenserine
- UCB 0599
- ATH 434
- ATV:aSyn
- Lu AF82422
- ABBV 0805
- PR 004
- UB 312
- MEDI 1341
- ENT 01
- Affitope PD01
- Affitope PD03
- Prasinezumab
- NPT 189
- anle 138b
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Alpha-Synuclein Inhibitors: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Alpha-Synuclein Inhibitors – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Alpha-Synuclein Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Alpha-Synuclein Inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Pre-registration)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- R-phenserine: Annovis Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ATH 434: Alterity Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- PR 004: Prevail Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Alpha-Synuclein Inhibitors Key Companies
- Alpha-Synuclein Inhibitors Key Products
- Alpha-Synuclein Inhibitors- Unmet Needs
- Alpha-Synuclein Inhibitors- Market Drivers and Barriers
- Alpha-Synuclein Inhibitors- Future Perspectives and Conclusion
- Alpha-Synuclein Inhibitors Analyst Views
- Alpha-Synuclein Inhibitors Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.